Department of Justice Posts Notice on NFPA Standards Activity Estimated reading time: 3–5 minutes The Department of Justice has published an official notice in the Federal Register on June 13, 2025. This notice is about the National Fire Protection Association (NFPA) and its work on developing safety standards. On May 1, 2025, the NFPA filed written notifications under section 6(a) of the National Cooperative Research and Production Act of 1993. The NFPA sent this notice to the Attorney General and the Federal Trade Commission. This is part of their regular process when updating their standards development activities. The NFPA’s filing is meant to extend the protection of the Act. This Act limits the recovery of antitrust damages to actual damages in certain situations. The NFPA has sent an updated list about its standards development. This includes information on their technical committees and assessment work. The NFPA releases information about its regulations, current standards, standards development, and assessment activities to the public. This information is available on the NFPA website at nfpa.org. The NFPA first notified the Department of Justice under this Act on September 20, 2004. The first notice was published in the Federal Register on October 21, 2004. The most recent notification before this one was filed on January 24, 2025. That notice was published on February 28, 2025. Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division, signed this latest notice. The notice was printed under [FR Doc. 2025-10768]. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Venture on Electrified Vehicle and Energy Storage Announced Estimated reading time: 3–5 minutes On April 3, 2025, a notice was filed with the Department of Justice Antitrust Division. It is about Electrified Vehicle and Energy Storage Evaluation–II (EVESE II). This notice is under the National Cooperative Research and Production Act of 1993. The purpose is to let the public know which companies are working together, and what the group intends to do. The notice lists the parties in the EVESE II venture. These are: BAE Systems Controls Inc., from Endicott, New York Castrol Limited, from Reading, United Kingdom Ford Motor Company, from Dearborn, Michigan Honda Development & Manufacturing of America, LLC, from Marysville, Ohio Komatsu America Corp, from Chicago, Illinois The companies plan to better understand battery energy storage systems. This work is for vehicles and other uses. They will study batteries in both normal use (called cycling) and in unusual or extreme use (called abuse). The research will focus on three main areas. These are: the battery cell, the battery module, and applications of the battery. The notice says this information is being made public to limit damages if there are any antitrust lawsuits. The Deputy Director for Civil Enforcement Operations in the Antitrust Division, Suzanne Morris, signed the notice. This entry is documented in the Federal Register, Volume 90, Number 113, Page 25081. The filing date was June 12, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Updates to NPSS Cooperative Research Group Estimated reading time: 2–3 minutes On May 7, 2025, the Southwest Research Institute’s Cooperative Research Group on Numerical Propulsion System Simulation (NPSS) submitted a notice to the Department of Justice and the Federal Trade Commission. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993. The notice reported changes in the group’s membership. Mitsubishi Power Aero, LLC, based in Glastonbury, Connecticut, has been added as a new member of the NPSS group. The notice also said that the period for the group’s work has been extended. The new end date for the research group’s project is now April 30, 2026. No other changes were made to the group’s membership or activities. The NPSS group is still accepting new members and plans to report any future changes as required. NPSS first filed for protection under the Act on December 11, 2013. A notice about this was published in the Federal Register on February 20, 2014. The latest notice before this one was filed with the Department of Justice on October 29, 2024. That notice was published on January 24, 2025, in the Federal Register. Suzanne Morris, Deputy Director of Civil Enforcement Operations in the Antitrust Division, signed the notice. This information can be found in the Federal Register, Volume 90, Number 113, on Friday, June 13, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Members Join Global Synchronizer Foundation Estimated reading time: 2–4 minutes On June 13, 2025, the Department of Justice published a notice in the Federal Register about changes in the Global Synchronizer Foundation (GSF). This notice is made under the National Cooperative Research and Production Act of 1993. GSF sent written notifications to both the Attorney General and the Federal Trade Commission. These notifications let the government know that four new members have joined the group. The new members are Proof Group from Menlo Park, California; T-RIZE Group from Montreal, Canada; Chainlink Labs from New York, New York; and BNP Paribas from Paris, French Republic. This update was filed by GSF on May 19, 2025. It is meant to help protect group members by limiting damages in some antitrust cases. The Act only allows antitrust plaintiffs to get actual damages in specific situations. No other changes were made to the group’s membership or planned activities. Membership in GSF is still open. GSF will keep submitting notifications when there are more membership changes. GSF first filed a notification with the Department of Justice on September 18, 2024. The Department published a notice about this on October 11, 2024. The last update before this one was filed on February 25, 2025, and a notice was published on March 7, 2025. Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division, signed this latest notice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Membership Changes in Subcutaneous Drug Development & Delivery Consortium, Inc. Estimated reading time: 3–5 minutes On May 23, 2025, the Subcutaneous Drug Development & Delivery Consortium, Inc. filed official notifications about changes in its group membership. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. The notification was sent to both the Attorney General and the Federal Trade Commission. The purpose was to extend protections under the Act. These protections limit antitrust plaintiffs to actual damages in certain cases. Four new parties have joined the consortium. They are Matchstick LLC from Boonton, New Jersey; Gilead Sciences, Inc. from Forest City, California; SHL Medical AG from Zug, Switzerland; and Regeneron Pharmaceuticals, Inc. from Tarrytown, New York. No other changes were made to the membership or to the planned activities of the group research project. Membership in the research project remains open. The Consortium plans to file more notifications if there are membership changes in the future. The original notification for the Consortium was filed on October 26, 2020. The Department of Justice published a notice about this in the Federal Register on December 3, 2020 (85 FR 78148). The most recent membership update before this one was filed on October 4, 2024. A notice of that filing was published in the Federal Register on December 20, 2024 (89 FR 104209). This announcement was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. [Federal Register, Volume 90, Number 113, Friday, June 13, 2025, Page 25081] Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DOJ Publishes Update on Rapid Response Partnership Vehicle Membership Estimated reading time: 3–5 minutes The Department of Justice Antitrust Division published a notice about changes in the Rapid Response Partnership Vehicle (RRPV) group. The notice appeared in the Federal Register on June 13, 2025. The RRPV is a group covered by the National Cooperative Research and Production Act of 1993. This law limits antitrust damages for certain group activities. The RRPV must tell the Attorney General and the Federal Trade Commission about changes in its members. On April 8, 2025, RRPV sent a written update to the proper authorities. This update shared new members joining the group and noted some leaving members. The notice lists all these changes. New Members Added Many organizations have joined the RRPV. Some new members include: Fisher BioServices, Inc., Rockville, MD Landmark Vaccines, Ltd., Loughborough, United Kingdom Rx Bandz, Locust Valley, NY Zeteo Tech, Inc., Sykesville, MD BioNet-Asia Co., Ltd, Bangkok, Thailand EmitBio, Inc., Morrisville, NC Matisse Pharmaceuticals, B.V., Geleen, Netherlands National Institute for Pharmaceutical Technology and Education, Inc., Minneapolis, MN ProtonDx, Ltd., London, United Kingdom BioVaxys Technology Corp., Etobicoke, Canada Enplas, Santa Clara, CA RHEAVITA BV, Ghent, Belgium And many more listed in the official document. The notice lists each new member, including companies from different countries and states in the United States. Members That Withdrew Some groups have left the RRPV. These include: TFF Pharmaceuticals, Inc., Fort Worth, TX Spring Discovery, Inc., San Carlos, CA Cue Health, Inc., San Diego, CA Deimos Biosciences, San Francisco, CA Other Details There were no other changes in membership or group activities. Membership in the RRPV is still open. RRPV plans to keep reporting any new changes in its membership. RRPV first filed for coverage under the antitrust law on January 5, 2024. The Department of Justice reported this in the Federal Register on April 16, 2024. The last membership update before this new one was filed on January 16, 2025 and published on February 28, 2025. The notice was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Publishes Notice on Medical CBRN Defense Consortium Membership Changes Estimated reading time: 2–3 minutes On June 13, 2025, the Department of Justice published a notice in the Federal Register about the Medical CBRN Defense Consortium (MCDC). The notice states that on April 1, 2025, the MCDC sent written notifications to the Attorney General and the Federal Trade Commission. This was done under the National Cooperative Research and Production Act of 1993. The notifications are meant to extend the law’s rules that limit antitrust plaintiffs to only actual damages in some cases. The notice lists three new members added to the MCDC: Defense Operations & Executions Solutions, Inc., W Melbourne, FL Systems & Technology Research, Woburn, MA The Trustees of the University of Pennsylvania, Philadelphia, PA No other changes have been made to the membership or planned activities of the MCDC. Membership in the group is still open. MCDC will continue to file more notifications when new members join. MCDC first filed a notification under this law on November 13, 2015. The Department of Justice published the first related notice on January 6, 2016 (81 FR 513). The last membership notification was filed on January 6, 2025. Another notice about this was published on February 28, 2025 (90 FR 10945). This most recent notice was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Companies Join Medical Technology Enterprise Consortium Estimated reading time: 4–6 minutes On April 7, 2025, the Medical Technology Enterprise Consortium (MTEC) filed a notification with the Department of Justice and the Federal Trade Commission. This was done under the National Cooperative Research and Production Act of 1993, section 6(a). Many new companies and organizations have been added as members of MTEC. The list includes AbViro LLC (Bethesda, MD), Advanced BioScience Laboratories, Inc. (Rockville, MD), Advanced Light Devices LLC (Las Vegas, NV), AI Optics, Inc. (New York, NY), Alamgir Research, Inc. dba ARIScience (Wayland, MA), Alcamena Stem Cell Therapeutics LLC (Halethorpe, MD), American Type Culture Collection (Manassas, VA), and BelleTorus Corp. (Cambridge, MA). The new members also include BIOPAC Systems, Inc. (Goleta, CA), Bitterroot Innovation LLC (Stevensville, MT), Business Enabled Acquisition and Technology, Inc. (San Antonio, TX), CereVu Medical, Inc. (San Francisco, CA), CleanBeam Technologies LLC (Greensboro, NC), Clearview Limited LLC dba Grant Engine (Durham, NC), Clyra Medical Technologies, Inc. (Tampa, FL), Cornell University (Ithaca, NY), CranioSense, Inc. (Bedford, MA), and DanForth Advisors (Waltham, MA). Other new members are Dephy, Inc. (Boxborough, MA), Evrys Bio LLC (Doylestown, PA), Global Resonance Technologies LLC (Shelbourne, VT), GreenLifeTech Corp. (Banner Elk, NC), Griffith University (Southport, Australia), Guide Biomedical Solutions LLC (Media, PA), Healables Digital Health, Inc. (Miami, FL), Health Helper Holdings, Inc. (Hollywood, FL), Heartland GS LLC (Delaware, OH), and Hemerus Medical LLC (St Paul, MN). The growing MTEC group also now includes Humanetics Corp. (Excelsior, MN), ICPupil, Ltd. (Tel Aviv, Israel), Innovative Design Labs, Inc. (Minneapolis, MN), IntegerBio, Inc. (Gaithersburg, MD), KBR (Houston, TX), Layer 3 Services Pty, Ltd. (Fyshwick, Australia), LumenAstra, Inc. (Boulder, CO), Matisse Pharmaceuticals, B.V. (Geleen, Netherlands), Medasense Biometrics, Ltd. (Ramat Gan, Israel), and MendaCel, Inc. (Laguna Beach, CA). Additional companies are MHCombiotic, Inc. (Calgary, Canada), Miracus LLC (Troy, MI), Molecular Technologies Laboratories dba InfinixBio (Galena, OH), Musculoskeletal Transplant Foundation, Inc. (Edison, NJ), Nanohmics, Inc. (Austin, TX), Neural Dynamics Technologies, Inc. (Newton, MA), Neurovascular Research and Design Corp. (Tucson, AZ), NextCure, Inc. (Beltsville, MD), Nostopharma LLC (Bethesda, MD), Obvius Robotics, Inc. (Sunrise, FL), Orgenesis, Inc. (Germantown, MD), pdx-tec LLC dba ppx-tec LLC (Jackson, MS), and Persistent Technology, Inc. (Alexandria, VA). More new members include President and Fellows of Harvard College (Cambridge, MA), PROYECCIÓN 22 SA DE CV (Uruapan, Mexico), Pulsethera, Inc. (Chestnut Hill, MA), Quest Consultants LLC dba Aerstone (Kensington, Morocco), Radiatric, Inc. (Washougal, WA), Results Group LLC (Glastonbury, CT), Roam Robotics, Inc. (San Francisco, CA), Safeguard Surgical (Tampa, FL), SafePush LLC (New Orleans, LA), Sciperio, Inc. (Orlando, FL), Senseye, Inc. (Austin, TX), SereNeuro Therapeutics, Inc. (Baltimore, MD), Signature Performance, Inc. (Omaha, NE), SilverStream Medical (Caesarea, Israel), Solascure, Ltd. (Cambridge, United Kingdom), Stoic Bio, Inc. (San Diego, CA), and Summit Technology Laboratory (Irvine, CA). Tillerline Associates LLC (Solon, OH), Tunnell Consulting, Inc. (Bethesda, MD), University of Arkansas for Medical Sciences (Little Rock, AR), Valinor Enterprises (Alexandria, VA), Vira Regen, Inc. (Salt Lake City, UT), and VitaKey, Inc. (Birmingham, AL) are also new parties to this group. No other changes have been made to the membership or the planned activity of the MTEC research project. Membership in this group research project remains open. MTEC will file more notifications when there are changes in membership. MTEC first filed with the Department of Justice on May 9, 2014. A notice was published in the Federal Register on June 9, 2014 (79 FR 32999). The last notification was filed on January 6, 2025, and was published on February 4, 2025 (90 FR 8943). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division, signed the notice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Issues Notice on Corrosion Under Insulation Research Group Estimated reading time: 3–5 minutes On January 6, 2025, the Cooperative Research Group Corrosion Under Insulation–Phase 2 (CUI–Phase 2) filed written notifications with the Attorney General and the Federal Trade Commission. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993. The notifications shared the names of all parties involved in the venture. These parties are: Conoco Phillips Company, Houston, TX Nanotech Inc., Houston, TX Armancell Engineered Systems Ltd., London, UNITED KINGDOM The Sherwin Williams Company, Cleveland, OH PPG Industries, Incorporated, Pittsburgh, PA International Paint LLC, Houston, TX Superior Products International II, Inc., Shawnee, KS Promat Incorporated, Maryville, TN Jotun A/S, Sandefjord, KINGDOM OF NORWAY Hempel A/S, Lyngby, KINGDOM OF DENMARK BP America Production Company, Houston, TX Air Products and Chemicals, Inc., Allentown, PA Aspen Aerogels, Inc., Marlborough, MA Exxonmobil Technology and Engineering, Spring, TX Equinor Energy AS, Stavanger, KINGDOM OF NORWAY The notice explained that these notifications were filed to use the Act’s provisions. These provisions can limit the damages recoverable by antitrust plaintiffs to actual damages in certain situations. The CUI–Phase 2 group will focus on testing protective coatings and insulation products. This includes insulative coatings using the TM21442 test method and similar methods. The tests will happen in both laboratory and field settings. Phase 2 of the project will also use laboratory setups to test new sensing technologies for Corrosion Under Insulation. Early tests will check a range of CUI sensors and compare how they perform. The test methods described above will be used. The CUI Phase 2 group has four main technical tasks: Performance testing of CUI Protective Coating/Insulation Systems Performance evaluation of CUI Insulative Coatings Performance evaluation of CUI Insulative Coatings Preliminary evaluation of CUI Sensors Suzanne Morris, Deputy Director of Civil Enforcement Operations in the Antitrust Division, signed the notice. The full notice appears in the Federal Register, Volume 90, Number 113 (Friday, June 13, 2025), on page 25080. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Notice of Changes in the Customer Experience Hub Membership Estimated reading time: 2–3 minutes On April 1, 2025, the Customer Experience Hub (CX Hub) sent new written notifications under the National Cooperative Research and Production Act of 1993. This Act is also called 15 U.S.C. 4301 et seq. These notifications were sent to both the Attorney General and the Federal Trade Commission. The purpose was to inform them of changes to CX Hub’s membership. The goal is to extend the Act’s protections that limit antitrust plaintiffs’ recovery to actual damages in certain cases. Four new organizations have joined the CX Hub: Ammonoosuc Community Health Services, Inc., Littleton, NH Merative US LP, Ann Arbor, MI Polished Technologies LLC, Chevy Chase, MD Washington State University Health Sciences, Spokane, WA Three organizations have withdrawn from the CX Hub: Ruth Health, Bronx, NY Spring Discovery, Inc., San Carlos, CA The Innovation Foundation at Oklahoma State University, Inc., Stillwater, OK No other changes were made to the group’s membership or planned activity. Membership in the CX Hub remains open. CX Hub will continue to file notifications about any membership changes. CX Hub filed its original notification under section 6(a) of the Act on January 11, 2024. The Department of Justice published a notice in the Federal Register on April 16, 2024 (89 FR 26929). The last notification was filed with the Department on January 3, 2025. A notice was published in the Federal Register on February 4, 2025 (90 FR 8942). This notice is issued by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division, Department of Justice. [FR Doc. 2025-10816 Filed 6-12-25; 8:45 am] BILLING CODE P Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Proposed Consent Decree Amendment for Youngstown, Ohio Estimated reading time: 5–8 minutes On June 6, 2025, the Department of Justice lodged a proposed Consent Decree Amendment with the United States District Court for the Northern District of Ohio. The case is titled United States et al. v. City of Youngstown, Ohio, Case No. 4:98-CV-2438. This proposed Amendment changes the Clean Water Act Consent Decree first entered in 2002. The Consent Decree and Long-Term Control Plan (LTCP) had addressed violations related to sewage and stormwater releases from the City of Youngstown’s combined sewer system. The LTCP had been approved by the U.S. EPA and the State of Ohio in 2015. The Amendment makes specific changes. First, it replaces the requirement to finish the “Wet Weather Facility Project” with a new requirement. The City must now complete the “CSO 6057 Control Measure Project.” This is an 80 million gallon per day (MGD) high-rate treatment facility. The facility will use cloth-disk filter media technology for the treatment of wet weather flows. Second, the Amendment replaces Chapter 5 of the LTCP with a new Chapter 5. This includes a Revised Implementation Schedule. The new schedule requires Youngstown to complete the “West-Division Interceptor Sewer Replacement.” This project is needed to reduce combined sewer overflows. The schedule for Phase 1 of the LTCP is changed as well. The changes set deadlines for the CSO 6057 Control Measure Project. The schedule for the “Mill Creek Project” will be compressed and accelerated. The Amendment also sets earlier deadlines to submit reports about new projects for LTCP Phase 2. There is now a 30-day public comment period on the proposed Consent Decree Amendment. Comments should be sent to the Assistant Attorney General, Environment and Natural Resources Division. Comments must mention United States et al. v. City of Youngstown, Ohio, D.J. Ref. No. 90-5-1-1-4383. Comments must be received within thirty days after June 12, 2025. Comments can be sent by email to the address listed in the notice, or by mail to: Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044-7611. Written comments may be made part of the public record. During the comment period, the full Consent Decree Amendment can be read and downloaded at: https://www.justice.gov/enrd/consent-decrees. Anyone needing help accessing the document can contact the Department of Justice by email or mail at the addresses given above. Laura Thoms, the Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division, submitted this notice. Reference: Federal Register, Volume 90, Number 112, June 12, 2025, Page 24817. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Releases Update on Utility Broadband Alliance, Inc. Membership Estimated reading time: 3–5 minutes The Department of Justice has released a notice about Utility Broadband Alliance, Inc. (UBBA) in the Federal Register on June 11, 2025. On April 16, 2025, UBBA sent notifications under section 6(a) of the National Cooperative Research and Production Act of 1993. The notifications were sent at the same time to the Attorney General and the Federal Trade Commission. The law is found at 15 U.S.C. 4301 and is known as “the Act.” The notice shows there are changes in the UBBA membership. These notifications are for the purpose of extending the Act’s rules. The Act limits antitrust plaintiffs to recovering only actual damages in certain cases. The new parties added to the UBBA group are: Actalent, Tulsa, OK Akin Gump Strauss Hauer & Feld LLP, Washington, DC Valmont Telecom, Omaha, NE Midwave Wireless, Vienna, VA Forsk US, Inc., Chicago, IL Morse Micro, Irvine, CA No other changes have been made to the group’s membership or activities. UBBA membership stays open. UBBA will send more notifications if membership changes. UBBA filed its first notice under section 6(a) of the Act on May 4, 2021. The Department of Justice published a notice in the Federal Register on June 10, 2021 (86 FR 30981). The last membership update was filed on January 17, 2025. A Federal Register notice was published about that on March 7, 2025 (90 FR 11552). The notice was signed by Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

MLCommons Association Updates Membership, Department of Justice Notice Issued Estimated reading time: 3–5 minutes On May 16, 2025, the MLCommons Association filed an official notice with the Attorney General and the Federal Trade Commission. This filing is required under section 6(a) of the National Cooperative Research and Production Act of 1993. The Act helps limit antitrust claims against members. It allows plaintiffs to collect only actual damages under certain situations. New Members Added MLCommons has added new members to its group. The following parties are now part of the organization: DataCrunch, Helsinki, Republic of Finland Nebius BV, Amsterdam, Kingdom of the Netherlands Scitix (SGP) Tech. PTE Ltd., Singapore, Republic of Singapore Persimmons, Inc., Milpitas, California The Constant Company, LLC, West Palm Beach, Florida MiTAC Computing Technology Corporation, Hsinchu, Republic of China (Taiwan) Chiara Bonfanti (individual member), Torino, Italian Republic Bhavesh Davda (individual member), Fremont, California Yongsang Park (individual member), Cupertino, California Jared Willard (individual member), Minneapolis, Minnesota Naeem Khoshnevis (individual member), Cambridge, Massachusetts Withdrawn Members Some parties have withdrawn from MLCommons. These are: Guangdong OPPO Mobile Telecommunications Corp., Ltd., DongGuan City, People’s Republic of China Neuchips Corporation, Hsinchu, Republic of China (Taiwan) VerifAI Inc, Palo Alto, California VMind Technologies, Inc., San Francisco, California Moreh Inc., Seoul, Republic of Korea NeuReality LTD., Ceaseria, State of Israel Neural Magic, Inc., Somerville, Massachusetts PowerML, Inc, Palo Alto, California UNTETHER AI, Toronto, Canada Turaco Strategy, LLC, Boulder, Colorado Membership Status and History No other changes have been made to the group’s membership or planned activities. Membership in the research project remains open. MLCommons will continue to file written notifications for all membership changes. The original notification for MLCommons was filed on September 15, 2020. The Department of Justice published this in the Federal Register on September 29, 2020. The last membership update was filed on February 26, 2025. That update appeared in the Federal Register on March 18, 2025. Notice Information This notice was published by Suzanne Morris, Deputy Director of Civil Enforcement Operations for the Antitrust Division of the Department of Justice. Federal Register Citation: 90 FR 24670, June 11, 2025. BILLING CODE 4410-11-P Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Proposes Consent Decree for Idaho Mine Cleanup Estimated reading time: 3–5 minutes On June 3, 2025, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the District of Idaho. This filing is part of a lawsuit called United States, et al. v. Nu-West Mining Inc. and Nu-West Industries, Inc., Civil Action No. 4:25-cv-00287-AKB. The case involves claims made by the United States under Sections 106 and 113(g) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as Superfund. The Superfund law deals with cleaning up hazardous waste sites. Claims are also made by the State of Idaho and the Shoshone-Bannock Tribes. The case focuses on the East Mill Dump Sub-Operable Unit (EMDSOU) at the North Maybe Mine Site in Idaho. The Consent Decree would resolve the government’s claims against the companies. The Decree would also resolve claims by Idaho and the Shoshone-Bannock Tribes under CERCLA Section 107 and 113(g)(2) for recovery of costs spent to address hazardous waste. According to the Consent Decree, the companies will perform cleanup activities at the EMDSOU. These actions are to follow the September 1, 2022, Interim Record of Decision. The companies must also pay for oversight costs to the State of Idaho, the Shoshone-Bannock Tribes, and the United States Fish and Wildlife Service. In return, the United States will not sue the companies under Sections 106 and 107(a) of CERCLA for the work agreed upon in the Consent Decree. The State and the Tribes will also not sue or take action under Sections 106 and 107(a) of CERCLA, the Idaho Environmental Protection & Health Act, the Hazardous Waste Management Act of 1983, and the Idaho Water Quality Act. The companies give the United States similar promises about not suing. The public can comment on the Consent Decree. Comments must be sent no later than thirty days after June 10, 2025. Comments should be sent to the Assistant Attorney General of the Environment and Natural Resources Division. Comments can be submitted by email or by mail. By email: “#{email}” By mail: Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044-7611 Written comments may be included in the public court docket. During the public comment period, the Consent Decree is available for review and download at: https://www.justice.gov/enrd/consent-decrees If assistance is needed to access the Consent Decree, requests can be made via the same email or mailing addresses provided. Signed, Kathryn C. Macdonald Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Requests Comments on Unfair Immigration-Related Employment Practices Complaint Form Estimated reading time: 3-5 minutes The Executive Office for Immigration Review (EOIR) of the Department of Justice (DOJ) has released a notice about the Unfair Immigration-Related Employment Practices Complaint Form, known as Form EOIR-58. EOIR plans to submit this information collection request to the Office of Management and Budget (OMB). This submission is part of the review process required by the Paperwork Reduction Act of 1995. The Department is encouraging public comments on this collection until August 4, 2025. People can comment on the following points: Is the form needed for the work of the agency? Is the estimate of the time to complete the form accurate? Is the information collected clear and useful? Can the burden on people filling out the form be reduced by using technology? What Does the Form Do? Section 274B of the Immigration and Nationality Act (INA) prohibits job discrimination based on citizenship or national origin. It also prohibits employers from taking action against someone for using their rights, or from asking workers for more or different documents than needed in a way that leads to discrimination. People who think their rights were violated can file a charge with the DOJ Immigrant and Employee Rights Section (IER). IER has 120 days to decide whether to file a complaint with the EOIR Office of the Chief Administrative Hearing Officer (OCAHO). If IER does not file, the person can file their own complaint with OCAHO using Form EOIR-58. Changes to the Form The DOJ is making updates to the form and instructions. Changes are non-substantive and aim to improve clarity, formatting, and grammar. The IER mailing address has been updated. The Privacy Act notice now mentions OCAHO’s System of Record Notice (SORN). The estimated time to complete the form has been revised. The instructions now explain differences between filing by mail and electronically, in preparation for expanded electronic filing options. Who Uses the Form? The people who use this form are individuals who want to report unfair immigration-related job practices under INA section 274B. Filling out the form is voluntary. People may also submit a complaint in writing if it meets the requirements in 28 CFR 68.7. Burden Estimates Estimated number of respondents yearly: 38 Estimated time to complete the form: 1 hour each Total annual burden: 38 hours Cost Estimates No filing fees for Form EOIR-58 Printing cost: About $15.00 per response (5 copies, average 150 pages at 10 cents per page) Postage cost (Priority Mail): About $10.10 per response Attorney cost if legal help is used: Average attorney wage is $72.67 per hour (according to U.S. Bureau of Labor Statistics) Maximum total estimated cost to the public: $3,715.26 (($15.00 + $10.10 + $72.67) x 38 responses) People who submit the form by email will not have printing or mailing costs. Most people send the form to OCAHO by U.S. mail. EOIR is working to fully implement electronic filing. Once available, this will eliminate printing and mailing costs for these forms. Contact for More Information For more details or a copy of the proposed form and instructions, contact Justine Fuga, Associate General Counsel, EOIR, at 5107 Leesburg Pike, Suite 2600, Falls Church, VA 22041, or by calling (703) 305-0265. For additional information, contact Darwin Arceo, Department Clearance Officer, Justice Management Division, Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC. Publication Information This notice was dated June 2, 2025, and appeared in the Federal Register on June 5, 2025, Volume 90, Issue 107, Pages 23960-23961. BILLING CODE 4410-30-P Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Proposes New Rule: Propionyl Chloride To Become a Controlled Chemical Estimated reading time: 3–5 minutes The Drug Enforcement Administration (DEA) is planning to make a new rule about propionyl chloride. This chemical is often used to make fentanyl and related dangerous drugs. The proposed rule would list propionyl chloride as a List I chemical. This means it will be controlled under the Controlled Substances Act (CSA). Why Is Propionyl Chloride Being Controlled? Propionyl chloride is used by illegal labs to make fentanyl, fentanyl analogues, and fentanyl-like substances. These drugs have caused many overdose deaths in the United States. Fentanyl is a powerful synthetic opioid. A small amount can be deadly. The DEA says propionyl chloride is important in making these drugs because it replaces another controlled chemical, propionic anhydride, during the process. What Will Happen If the Rule Is Finalized? Everyone who makes, sells, imports, or exports propionyl chloride will have to follow CSA rules. There will not be a threshold amount. This means any amount of propionyl chloride, even a tiny amount, will be regulated. Chemical mixtures that contain any propionyl chloride will also be regulated, no matter the concentration. No automatic exemptions will be given, but companies can apply for an exemption. Comment Period Open Until July 3, 2025 The DEA is asking for comments from the public about this rule. Comments need to be sent in by July 3, 2025. People can comment online at www.regulations.gov or by mail. All comments become part of the public record, so personal information could be seen by others. How Does Propionyl Chloride Make Fentanyl? Fentanyl and related drugs are not found in nature. They are made from chemicals. Propionyl chloride is used in several steps of different methods for making fentanyl. These methods include the “Janssen,” “Siegfried,” and “Gupta” processes. In these, propionyl chloride reacts with other chemicals to make important fentanyl building blocks. Illegal labs use propionyl chloride because it is easy to get and is not currently regulated. Making it a List I chemical will make it harder for illegal labs to get the chemical. Information Gathered by the DEA The DEA got six public comments about this action. Three comments supported the rule. Three others mentioned possible problems. Some said that propionyl chloride can also be used in research labs or in making pharmaceutical or agricultural products. Some worried that controlling this chemical would make it harder and more expensive for researchers to get. Others said most people who use it already have the paperwork to buy it. What Will Be Required If the Rule Takes Effect? Registration: Anyone making, selling, importing, or exporting propionyl chloride (or mixtures with it) must register with the DEA. Records and Reports: Records of transactions must be kept for two years. Any odd transactions, losses, or thefts must be reported. Shipping: Importing or exporting must follow DEA rules. Security: Companies must provide strong controls to prevent theft or misuse. Inspections: The DEA can inspect businesses handling this chemical. Legal Risk: Doing anything with propionyl chloride that is not allowed by law is a crime. There will be a temporary 30-day exemption for people already handling propionyl chloride. During this time, they must apply for registration or exemption. Economic and Legal Effects The DEA does not expect this rule to have big costs for companies. The main cost will be registration fees ($3,699 for manufacturers and $1,850 for distributors, importers, and exporters). Companies already making opioid medicines with fentanyl should already have DEA registration. The DEA thinks very few businesses will be impacted. The rule follows all proper government and legal procedures. It does not interfere with state laws or other government powers. Next Steps The DEA is taking comments until July 3, 2025. After that, they will decide if the rule should go into effect. Contact Information For more details, contact Terrence L. Boos at the DEA (571) 362-3249. How To Comment Online: www.regulations.gov (Docket No. DEA-1189) Mail: Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, VA 22152 All comments must be sent or postmarked by July 3, 2025. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Proposes Rule to Place 4-Fluoroamphetamine in Schedule I Estimated reading time: 3–5 minutes On June 3, 2025, the Drug Enforcement Administration (DEA) announced a proposed rule to place the substance 4-fluoroamphetamine (4-FA) in Schedule I of the Controlled Substances Act (CSA). What Is 4-Fluoroamphetamine (4-FA)? 4-FA is a central nervous system stimulant. It is similar to amphetamine and methamphetamine, which are already controlled substances. 4-FA has no approved medical use in the United States. Why Is the DEA Proposing This Rule? This proposal is partly to help the United States meet its requirements under the 1971 Convention on Psychotropic Substances. The United Nations international body placed 4-FA in Schedule II of its convention in 2018. The DEA is acting to control 4-FA following these international decisions and U.S. law. What Evidence Did the DEA Review? The DEA and the Department of Health and Human Services (HHS) reviewed scientific studies, medical information, case reports, and law enforcement data. Their findings show that 4-FA: Acts like powerful stimulant drugs. Is being abused in the United States and elsewhere. Is found in illegal drug markets. Can cause serious health problems, including death. Has no accepted medical use. Details From the Scientific Review 4-FA produces effects similar to those of schedule I and II drugs such as amphetamine, methamphetamine, cocaine, and MDMA. It increases levels of certain chemicals in the brain and produces feelings of euphoria and high energy. People have taken it without medical advice, and it has been abused in many states. Law enforcement tested drug samples and found 269 reports of 4-FA in drug exhibits from January 2011 to December 2023. Most users are young adults. The drug can be taken by swallowing or snorting. 4-FA has caused emergency department visits, overdoses, and at least five deaths. Common effects include fast heartbeat, high blood pressure, headache, agitation, and fever. No studies show that it has accepted medical use or that it is safe for use with medical supervision. Proposed Rule Details If the rule is finalized, 4-FA will become a Schedule I controlled substance. This means: Only DEA-registered persons can manufacture, distribute, import, export, research, or possess 4-FA. Those who wish to handle 4-FA will need DEA registration. Those who do not register must surrender or transfer their 4-FA stock. 4-FA will need to be stored securely. Quotas will limit manufacturing. Inventories must be taken and records kept. Reports must be submitted to the DEA. Order forms must be used for transactions. Import and export rules will apply. Activities with 4-FA not allowed under the law may lead to criminal, civil, or administrative penalties. Comment Period and Hearing Requests Comments about the proposed rule must be submitted to the DEA by July 3, 2025. People may also request a hearing by that date, showing their interest and objections. Regulatory Effects This proposal will not have a big economic impact on small businesses. There is no evidence of legitimate use for 4-FA, except in some scientific research. The DEA says this rule does not add new paperwork requirements for businesses or government agencies, but existing recordkeeping rules must be followed. How to Comment Comments can be sent electronically through the Federal eRulemaking Portal at www.regulations.gov. Paper comments can be mailed to the DEA in Springfield, Virginia. All comments are part of the public record unless marked as confidential. Conclusion The DEA is proposing full control of 4-FA due to high potential for abuse and no accepted medical use. If the rule becomes final, 4-FA and related substances will be placed in Schedule I and subject to strict regulations. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Corrects Rule to Add 2-Methyl AP-237 to Schedule I Estimated reading time: 1–7 minutes On June 3, 2025, the Drug Enforcement Administration (DEA) issued a correcting amendment in the Federal Register. This update concerns the controlled substance 2-methyl AP-237. What is 2-methyl AP-237? 2-methyl AP-237 is a synthetic drug. Its full name is 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one. It belongs to a group of drugs called synthetic opioids. These drugs can be changed in small ways in a lab to make similar versions. Why was there a correction? The DEA first published a final order on March 15, 2024. This order put 2-methyl AP-237 and its related chemical forms into Schedule I of the Controlled Substances Act. Schedule I drugs are thought to have a high chance for abuse and no approved medical use. The order said this new rule would start 30 days later, on April 15, 2024. Before this date came, the DEA published another rule about three different drugs. These drugs—etodesnitazene, N-pyrrolidino etonitazene, and protonitazene—were also put into Schedule I. Because these two rules overlapped, there was a mistake in the text about how 2-methyl AP-237 should be listed. What does the correction do? The correction fixes the list in the government rules. It adds 2-methyl AP-237 to 21 CFR 1308.11(b), which is the official list for Schedule I drugs. It also adds its special drug code number, 9664. All other parts of the rule stay the same. The correction says 2-methyl AP-237 has been in Schedule I since April 15, 2024. The change in the text does not change when the rule started. How does this affect the law? Since April 15, 2024, it has been illegal to make, sell, or have 2-methyl AP-237 without special permission. This applies to the drug and any chemical forms that are possible. Who signed this correction? The correction was signed on May 27, 2025, by DEA Acting Administrator Robert J. Murphy. Heather Achbach, DEA Federal Register Liaison Officer, submitted the document for publication. Where can you get more information? Questions can go to Dr. Terrence L. Boos at the DEA Drug and Chemical Evaluation Section. The phone number is (571) 362-3249. Summary 2-methyl AP-237 is now clearly listed as a Schedule I controlled substance. The rule has been effective since April 15, 2024. The correction fixes a technical mistake and makes the listing official and clear. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Issues Notice on Immigration Court Forms Estimated reading time: 1–3 minutes The Department of Justice (DOJ) has published a notice about its collection of information for two important forms. These forms are used in immigration cases. The forms are called EOIR-60 and EOIR-61. The forms let an attorney or representative help a person, called a “pro se respondent,” with a legal document for the Board of Immigration Appeals or the Immigration Court. This is called a “limited appearance.” It means the lawyer only helps with one document. EOIR-60 is for the Board of Immigration Appeals. EOIR-61 is for the Immigration Court. Starting in July 2024, people can file these forms online using the EOIR Courts and Appeals System Respondent Access Portal (RAP). The forms have been updated. They no longer need to be mailed only. The EOIR Policy Manual now gives filing instructions. The new forms also let people show if they sent the paperwork to the other side electronically through ECAS. A change was made to the privacy notice on the forms. The correct system of records is JUSTICE/EOIR-003. More case information is now available online in English or Spanish at the EOIR Automated Case Information System. The EOIR-60 form now has a note to say that “limited appearance” is not allowed in Department of Homeland Security (DHS) proceedings that the Board controls. The DOJ asks for comments about the forms. People have 60 days, until August 4, 2025, to respond. They can give thoughts on whether the forms are needed, if the estimates of time are correct, and how to make the process easier. Here are details about the information collection: Type of Collection: The DOJ is updating and extending forms already in use. Forms: EOIR-60 (Board of Immigration Appeals) and EOIR-61 (Immigration Court). Who Fills Them Out: Individuals, attorneys, and representatives helping pro se respondents. Filling out the form is required to help with a document. Estimate of Use: About 40 people will fill out EOIR-60 each year. About 22,018 will fill out EOIR-61 each year. Time to Complete: Each form takes about 6 minutes. Total Annual Burden: 2,206 hours for everyone together. Cost: There is no fee to send in the forms. Forms can be sent online, saving postage costs. The estimated cost for a legal expert to fill out the form is $7.27 per time. The yearly cost for everyone combined is about $160,310.02. The DOJ’s contact for more information is Justine Fuga, Associate General Counsel at EOIR. People can also contact Darwin Arceo, Department Clearance Officer, for other questions. The notice was published on June 3, 2025. It is a public invitation for feedback on these forms and their collection. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Requests Public Comment on DEA Registration Forms Estimated reading time: 3–5 minutes On June 3, 2025, the Department of Justice (DOJ) announced a request for public comments regarding an extension of an information collection. This collection is for the Drug Enforcement Administration (DEA) registration forms. The specific forms are DEA Form 225, DEA Form 225a for renewals, and DEA Form 225b for chain renewals. The DOJ is required to obtain approval from the Office of Management and Budget (OMB) before continuing to collect this information. They must do this under the Paperwork Reduction Act of 1995. The DOJ invites public comments for 30 days, ending July 3, 2025. The public may comment on the accuracy of time estimates for the forms, suggest better ways to collect information, and more. Anyone interested can provide comments online by visiting www.reginfo.gov/public/do/PRAMain. People may search for this collection using the title or OMB Control Number 1117-0012. The forms are used as part of the Controlled Substances Act. All businesses and individuals that manufacture, distribute, import, export, research, or analyze controlled substances must register with the DEA. These records keep controlled substances secure and ensure only approved people handle them. Here are the key details: Type of Collection: Extension, without changes, of a current approval. Title: Application for Registration, Registration Renewal, Affidavit for Chain Renewal. Forms: DEA 225, 225a, 225b. Affected Groups: Businesses, not-for-profit institutions, and government agencies. Number of Respondents: 16,560 per year. Estimated Time Per Response: 0.20066 hours. Frequency: Once per year. Total Annual Time Burden: 3,323 hours. Total Annual Non-Labor Cost: $0. Obligation: Required for businesses or individuals wanting to handle controlled substances. Anyone with questions or requests for copies of the forms or instructions can contact Heather E. Achbach, Regulatory Drafting and Policy Support Section, DEA. The contact address is 8701 Morrissette Drive, Springfield, Virginia 22152, telephone (571) 776-3882, or by email. For more information, the public can contact Darwin Arceo, Department Clearance Officer, at the DOJ’s Justice Management Division in Washington, DC. This information collection will stay in effect for up to three years if approved. Renewals will occur as needed for continued authorization. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

ANI Pharmaceuticals Inc. Applies to Import Controlled Substances Estimated reading time: 1–7 minutes ANI Pharmaceuticals Inc. has asked the Drug Enforcement Administration (DEA) to approve its registration as an importer of two controlled substances: Levorphanol and Tapentadol. Levorphanol has a drug code of 9220 and is listed as a Schedule II substance. ANI Pharmaceuticals plans to import Levorphanol for distribution to customers. Tapentadol has a drug code of 9780 and is also a Schedule II substance. ANI Pharmaceuticals will only import small amounts of Tapentadol. The Tapentadol is for internal research and making reference standards. No other uses of these drugs are allowed under this registration. Only bulk manufacturers already registered for these drugs, or new applicants, may send comments or objections about ANI’s application. Comments and objections must be sent electronically through the Federal eRulemaking Portal at https://www.regulations.gov. The deadline is July 2, 2025. Anyone asking for a hearing about this application must send their written request by July 2, 2025. Requests for hearings must be sent to several DEA addresses in Springfield, Virginia. These addresses include the Hearing Clerk/OALJ, the DEA Federal Register Representative/DPW, and the Administrator. The DEA says it will approve permit applications only if ANI Pharmaceuticals’ business activity matches what is allowed under U.S. law 21 U.S.C. 952(a)(2). ANI’s authorization will not cover importing FDA-approved or non-approved finished dosage forms for sale. The notice was signed by Matthew Strait, Deputy Assistant Administrator, and published in the Federal Register on June 2, 2025. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Veranova, L.P. Applies to Manufacture Controlled Substances in Bulk Estimated reading time: 2–3 minutes Veranova, L.P. has sent an application to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of several controlled substances. The request was made on April 17, 2025. The proposed location for manufacturing is 25 Patton Road, Pharmaceutical Service, Devens, Massachusetts 01434-3803. The company seeks to produce the following basic classes of controlled substances: Lysergic Acid Diethylamide (LSD) (Drug Code 7315), Schedule I 3,4-Methylenedioxymethamphetamine (MDMA) (Drug Code 7405), Schedule I Dimethyltryptamine (Drug Code 7435), Schedule I Amphetamine (Drug Code 1100), Schedule II Methylphenidate (Drug Code 1724), Schedule II Nabilone (Drug Code 7379), Schedule II Hydrocodone (Drug Code 9193), Schedule II Levorphanol (Drug Code 9220), Schedule II Thebaine (Drug Code 9333), Schedule II Alfentanil (Drug Code 9737), Schedule II Remifentanil (Drug Code 9739), Schedule II Sufentanil (Drug Code 9740), Schedule II The DEA states that Veranova plans to use the substances to support manufacturing and analytical testing at its other DEA-registered manufacturing facility. No other activities for these drug codes are authorized under this registration. Anyone who is a registered bulk manufacturer of these drugs, or is applying to become one, can submit comments or object to the proposed registration. Comments and objections must be sent electronically by August 1, 2025. To submit a comment, visit https://www.regulations.gov and follow the instructions. Once a comment is submitted, you will get a Comment Tracking Number as proof. Comments may not appear immediately online. A written request for a hearing about this application must also be filed by the deadline. This notice was signed by Matthew Strait, Deputy Assistant Administrator at the DEA. The official notice is document number 2025-09929 and was published in the Federal Register Volume 90, Number 104, on June 2, 2025. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.